Avosentan is primarily investigated for its potential therapeutic applications in the treatment of various kidney-related conditions, particularly those involving proteinuria and diabetic nephropathy. It functions as an endothelin receptor antagonist, which helps in reducing the progression of kidney damage by blocking the effects of endothelin, a substance that can constrict blood vessels and increase blood pressure. This makes it particularly useful in managing chronic kidney diseases where excessive protein in the urine and high blood pressure are prevalent. Additionally, its role in improving renal outcomes has been a significant focus in clinical trials, aiming to provide a better quality of life for patients suffering from severe kidney disorders.